Lee's Pharmaceutical Holdings Limited
Lee's Pharmaceutical Holdings Limited Fundamental Analysis
Lee's Pharmaceutical Holdings Limited (0950.HK) shows moderate financial fundamentals with a PE ratio of 7.28, profit margin of 6.81%, and ROE of 5.44%. The company generates $1.4B in annual revenue with strong year-over-year growth of 32.95%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 55.4/100 based on profitability, valuation, growth, and balance sheet metrics. The C grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze 0950.HK's fundamental strength across five key dimensions:
Efficiency Score
Weak0950.HK struggles to generate sufficient returns from assets.
Valuation Score
Excellent0950.HK trades at attractive valuation levels.
Growth Score
Moderate0950.HK shows steady but slowing expansion.
Financial Health Score
Excellent0950.HK maintains a strong and stable balance sheet.
Profitability Score
Weak0950.HK struggles to sustain strong margins.
Key Financial Metrics
Is 0950.HK Expensive or Cheap?
P/E Ratio
0950.HK trades at 7.28 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, 0950.HK's PEG of 1.17 indicates fair valuation.
Price to Book
The market values Lee's Pharmaceutical Holdings Limited at 0.37 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 2.93 times EBITDA. This is generally considered low.
How Well Does 0950.HK Make Money?
Net Profit Margin
For every $100 in sales, Lee's Pharmaceutical Holdings Limited keeps $6.81 as profit after all expenses.
Operating Margin
Core operations generate 7.83 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $5.44 in profit for every $100 of shareholder equity.
ROA
Lee's Pharmaceutical Holdings Limited generates $3.26 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Lee's Pharmaceutical Holdings Limited generates strong operating cash flow of $367.35M, reflecting robust business health.
Free Cash Flow
Lee's Pharmaceutical Holdings Limited generates strong free cash flow of $324.98M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $0.55 in free cash annually.
FCF Yield
0950.HK converts 45.61% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
7.28
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
1.17
vs 25 benchmark
P/B Ratio
Price to book value ratio
0.37
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.50
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.13
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.06
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.05
vs 25 benchmark
ROA
Return on assets percentage
0.03
vs 25 benchmark
ROCE
Return on capital employed
0.05
vs 25 benchmark
How 0950.HK Stacks Against Its Sector Peers
| Metric | 0950.HK Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 7.28 | 28.45 | Better (Cheaper) |
| ROE | 5.44% | 763.00% | Weak |
| Net Margin | 6.81% | -45265.00% (disorted) | Weak |
| Debt/Equity | 0.13 | 0.34 | Strong (Low Leverage) |
| Current Ratio | 1.06 | 2795.60 | Neutral |
| ROA | 3.26% | -16588.00% (disorted) | Weak |
0950.HK outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Lee's Pharmaceutical Holdings Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
15.38%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
47.65%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
-39.21%
Industry Style: Defensive, Growth, Innovation
Declining